Dyne Therapeutics
DYN
15.50
-0.53
-3.31%
Dyne Therapeutics
US · DYN
#2540 by market cap
Listed 2020
15.50
-0.53
-3.31%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 12.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.70% -12.59pp
- Institutions
- 301 +4
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund69.03%
VC/PE Fund17.70%
Hedge Fund12.02%
Public Company3.71%
Government Pension Fund0.64%
Individual/Insider0.27%
Private Company0.17%
Insurance Company0.16%
Endowment Fund0.13%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
18.60% · 34.85M sh
BlackRock
7.72% · 14.47M sh
Janus Henderson Group plc
6.40% · 12.00M sh
FMR
5.95% · 11.15M sh
State Street Global Advisors
4.35% · 8.16M sh
Vanguard Capital Management, LLC
4.03% · 7.55M sh
Orbis Investment Management Limited
3.74% · 7.01M sh
Vanguard Portfolio Management, LLC
2.50% · 4.69M sh
TCG Crossover Management, LLC
2.46% · 4.62M sh
Geode Capital Management, LLC
2.35% · 4.40M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| John Cox | Chief Executive Officer | 0.10% |
| Catherine Stehman-Breen | Independent Director | 0.05% |
| Oxana Beskrovnaya | Chief Innovation Officer | 0.04% |
| Johanna Friedl-Naderer | Chief Commercial Officer | 0.03% |
| Douglas Kerr | Head of Research & Development and Chief Medical Officer | 0.02% |
| Brian Posner | Independent Director | 0.01% |
| Richard Scalzo | Former Senior VP and Head of Finance & Administration | 0.01% |
| Erick Lucera | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | 0.01% |
| Atlas Venture Advisors, Inc. | -- | -- |
| Edward Hurwitz | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-12 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -2,604 | $16.82 |
| 2026-11-12 | John Cox | Chief Executive Officer | Intent to Sell (Form 144) | -5,513 | $16.82 |
| 2026-10-19 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Other Acquisition | +8,000 | -- |
| 2026-10-19 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +12,000 | $16.27 |
| 2026-10-01 | Brian Posner | Independent Director | Open Market Acquisition | +2,500 | $16.00 |
| 2026-09-07 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -5,035 | $18.88–24.35 |
| 2026-09-07 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -35 | $18.89 |
| 2026-09-07 | John Cox | Chief Executive Officer | Automatic Disposition | -5,658 | $18.88 |
| 2026-09-07 | Johanna Friedl-Naderer | Chief Commercial Officer | Automatic Disposition | -1,085 | $18.88–24.35 |
| 2026-09-03 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -5,000 | $24.35 |
| 2026-08-13 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -2,586,928 | $25.00–26.20 |
| 2026-08-12 | Douglas Kerr | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -1,556 | $26.28 |
| 2026-08-12 | John Cox | Chief Executive Officer | Automatic Disposition | -4,986 | $26.28 |
| 2026-08-12 | Erick Lucera | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | Automatic Disposition | -1,797 | $26.28 |
| 2026-08-12 | Johanna Friedl-Naderer | Chief Commercial Officer | Automatic Disposition | -226 | $26.28 |
| 2026-07-26 | Forbion Capital Partners B.V. | -- | Automatic Disposition | -261,460 | $25.50–26.04 |
| 2026-07-06 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -772,451 | $22.79–23.62 |
| 2026-07-06 | Atlas Venture Advisors, Inc. | -- | Open Market Disposition | -5,000 | $23.61 |
| 2026-06-28 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -504,695 | $21.14–21.28 |
| 2026-06-24 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -267,760 | $21.02–21.13 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Dyne Therapeutics discussion 0 comments